0.3815
price up icon10.61%   0.0366
after-market アフターアワーズ: .38 -0.0015 -0.39%
loading
前日終値:
$0.3449
開ける:
$0.3535
24時間の取引高:
14.96M
Relative Volume:
1.01
時価総額:
$89.54M
収益:
$44.05M
当期純損益:
$-156.16M
株価収益率:
-0.5552
EPS:
-0.6872
ネットキャッシュフロー:
$-158.51M
1週間 パフォーマンス:
-12.12%
1か月 パフォーマンス:
+0.37%
6か月 パフォーマンス:
-86.28%
1年 パフォーマンス:
-70.20%
1日の値動き範囲:
Value
$0.3495
$0.397
1週間の範囲:
Value
$0.3213
$0.47
52週間の値動き範囲:
Value
$0.3213
$3.87

Gossamer Bio Inc Stock (GOSS) Company Profile

Name
名前
Gossamer Bio Inc
Name
セクター
Healthcare (1114)
Name
電話
(858) 684-1300
Name
住所
3115 MERRYFIELD ROW, SAN DIEGO, CA
Name
職員
162
Name
Twitter
@GossamerBio
Name
次回の収益日
2026-03-19
Name
最新のSEC提出書
Name
GOSS's Discussions on Twitter

Compare GOSS vs VRTX, REGN, ALNY, ARGX, INSM

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
GOSS icon
GOSS
Gossamer Bio Inc
0.3815 80.95M 44.05M -156.16M -158.51M -0.6872
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 113.96B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 78.41B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 40.85B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 42.05B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 29.99B 606.42M -1.28B -997.58M -6.403

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-24 ダウングレード Barclays Overweight → Equal Weight
2026-02-24 ダウングレード Leerink Partners Outperform → Market Perform
2026-02-24 ダウングレード Wedbush Outperform → Neutral
2026-01-28 開始されました Barclays Overweight
2025-09-10 アップグレード UBS Neutral → Buy
2025-07-14 開始されました Scotiabank Sector Outperform
2024-06-25 開始されました Oppenheimer Outperform
2024-04-05 再開されました Wedbush Outperform
2023-07-27 ダウングレード UBS Buy → Neutral
2023-03-07 ダウングレード Raymond James Outperform → Mkt Perform
2023-03-01 開始されました Guggenheim Neutral
2022-12-07 ダウングレード Barclays Overweight → Equal Weight
2022-12-07 ダウングレード JP Morgan Neutral → Underweight
2022-12-07 ダウングレード SMBC Nikko Outperform → Neutral
2022-10-20 開始されました Goldman Buy
2022-09-21 開始されました JP Morgan Neutral
2022-09-19 開始されました Wedbush Outperform
2022-04-18 開始されました Raymond James Outperform
2022-04-06 開始されました UBS Buy
2022-01-10 アップグレード SMBC Nikko Neutral → Outperform
2021-11-09 再開されました Cantor Fitzgerald Overweight
2021-09-21 再開されました Piper Sandler Overweight
2020-06-29 開始されました H.C. Wainwright Buy
2020-04-22 開始されました Piper Sandler Overweight
2020-02-27 開始されました Barclays Overweight
2019-12-03 再開されました BofA/Merrill Buy
2019-10-30 開始されました Berenberg Buy
2019-03-05 開始されました Barclays Overweight
2019-03-05 開始されました BofA/Merrill Buy
2019-03-05 開始されました Evercore ISI Outperform
2019-03-05 開始されました SVB Leerink Outperform
すべてを表示

Gossamer Bio Inc (GOSS) 最新ニュース

pulisher
Mar 25, 2026

Options Flow: Is Gossamer Bio Inc a stock for growth or value investorsPortfolio Performance Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn

Mar 25, 2026
pulisher
Mar 24, 2026

Gossamer Bio (GOSS) continues downtrend despite impressive revenue - MSN

Mar 24, 2026
pulisher
Mar 24, 2026

Setup Watch: Should I set a stop loss on Gossamer Bio IncTrade Entry Report & Smart Investment Allocation Insights - baoquankhu1.vn

Mar 24, 2026
pulisher
Mar 24, 2026

Gossamer Bio (GOSS) Continues Downtrend Despite Impressive Revenue - Insider Monkey

Mar 24, 2026
pulisher
Mar 24, 2026

683 Capital (GOSS) reports 3.90% position including exercisable warrants - Stock Titan

Mar 24, 2026
pulisher
Mar 23, 2026

Gossamer Bio downgraded by Cantor on unclear regulatory path for seralutinib - Seeking Alpha

Mar 23, 2026
pulisher
Mar 23, 2026

This Box Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga

Mar 23, 2026
pulisher
Mar 23, 2026

Gossamer Bio (GOSS) Downgraded to Neutral by Cantor Fitzgerald | - GuruFocus

Mar 23, 2026
pulisher
Mar 23, 2026

Cantor Fitzgerald Reiterates "Neutral" Rating for Gossamer Bio (NASDAQ:GOSS) - MarketBeat

Mar 23, 2026
pulisher
Mar 23, 2026

Cantor Fitzgerald cuts Gossamer Bio stock rating after trial miss By Investing.com - Investing.com South Africa

Mar 23, 2026
pulisher
Mar 23, 2026

Q3 EPS Estimates for Gossamer Bio Boosted by HC Wainwright - MarketBeat

Mar 23, 2026
pulisher
Mar 22, 2026

Gossamer Bio, Inc.(NasdaqGS:GOSS) dropped from S&P Biotechnology Select Industry Index - marketscreener.com

Mar 22, 2026
pulisher
Mar 21, 2026

Gossamer Bio (GOSS) reports topline phase 3 results for seralutinib in pulmonary arterial hypertension - MSN

Mar 21, 2026
pulisher
Mar 20, 2026

Gossamer Bio (GOSS) reprices Chief Medical Officer stock options - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

Gossamer Bio (GOSS) reprices EVP Caryn Peterson’s stock options to $0.45 - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

Gossamer Bio (GOSS) cuts Chief Commercial Officer option strike prices to $0.45 - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

Gossamer Bio (GOSS) reprices CEO stock options to $0.45 strike - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

Gossamer Bio (GOSS) reprices multiple stock option grants for COO/CFO - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

Gossamer Bio (GOSS) cuts EVP Waage option strike to $0.45 in 2.07M-share repricing - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

Analysts revise forecasts for Gossamer Bio (GOSS) amid uncertain regulatory environment - MSN

Mar 20, 2026
pulisher
Mar 20, 2026

Analysts Revise Forecasts for Gossamer Bio (GOSS) Amid Uncertain Regulatory Environment - Yahoo Finance

Mar 20, 2026
pulisher
Mar 20, 2026

Biotech company cuts half its staff after disappointing trial sees stock plummet - KRON4

Mar 20, 2026
pulisher
Mar 20, 2026

Layoff Tracker: Gossamer, BiomX Reveal Hefty Staff Cuts - BioSpace

Mar 20, 2026
pulisher
Mar 19, 2026

Big Picture: Does Gossamer Bio Inc stock benefit from AI growth2026 Buyback Activity & Accurate Trade Setup Notifications - baoquankhu1.vn

Mar 19, 2026
pulisher
Mar 19, 2026

5 Most Active Penny Stocks to Buy - Insider Monkey

Mar 19, 2026
pulisher
Mar 19, 2026

GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails - GlobeNewswire

Mar 19, 2026
pulisher
Mar 19, 2026

Guggenheim Remains a Hold on Gossamer Bio (GOSS) - The Globe and Mail

Mar 19, 2026
pulisher
Mar 19, 2026

Gossamer Bio Inc Stock (ISIN: US38198T1034) Faces Uncertainty After Phase 3 Setback and Widening Los - AD HOC NEWS

Mar 19, 2026
pulisher
Mar 19, 2026

[EFFECT] Gossamer Bio, Inc. SE... | GOSS SEC FilingForm EFFECT - Stock Titan

Mar 19, 2026
pulisher
Mar 18, 2026

Calif. biotech company lays off almost half of staff after 78% stock drop - SFGATE

Mar 18, 2026
pulisher
Mar 18, 2026

Gossamer Bio plans FDA talks after narrow miss in key pivotal study, stock sinks - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

Gossamer Bio 2025 Annual Report: Seralutinib PAH Clinical Development, FDA Path, and Regulatory Strategy Insights - Minichart

Mar 18, 2026
pulisher
Mar 18, 2026

Gossamer Bio, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire

Mar 18, 2026
pulisher
Mar 18, 2026

Gossamer Bio (NASDAQ:GOSS) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.

Mar 18, 2026
pulisher
Mar 18, 2026

Gossamer Bio Inc Stock (ISIN: US38198T1034) Faces Investor Lawsuit After Phase 3 Trial Failure and E - AD HOC NEWS

Mar 18, 2026
pulisher
Mar 17, 2026

Gossamer Bio (GOSS) reports Q4 loss, beats revenue estimates - MSN

Mar 17, 2026
pulisher
Mar 17, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, ... - Bluefield Daily Telegraph

Mar 17, 2026
pulisher
Mar 17, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc.GOSS - ChartMill

Mar 17, 2026
pulisher
Mar 17, 2026

Gossamer Bio earnings missed by $0.02, revenue topped estimates - Investing.com Canada

Mar 17, 2026
pulisher
Mar 17, 2026

Gossamer Bio Q4 2025 Earnings: Revenue Beats Forecasts, Loss WidensNews and Statistics - IndexBox

Mar 17, 2026
pulisher
Mar 17, 2026

Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance

Mar 17, 2026
pulisher
Mar 17, 2026

GOSS Exceeds Q4 Revenue Expectations Amid PROSERA Results Analys - GuruFocus

Mar 17, 2026
pulisher
Mar 17, 2026

Gossamer Bio Inc. announced that, during the evaluation of the impact of the Prosera trial results on its clinical programs, it has suspended new patient enrollment in the Phase III Seranata study for patients with progressive fibrosing interstitial lung disease (Ph - Bitget

Mar 17, 2026
pulisher
Mar 17, 2026

Gossamer Bio: Fourth Quarter Financial Results Overview - Bitget

Mar 17, 2026
pulisher
Mar 17, 2026

Gossamer Bio Q4 net loss widens - TradingView

Mar 17, 2026
pulisher
Mar 17, 2026

Gossamer Bio (NASDAQ: GOSS) registers up to $200M shelf for equity, debt - Stock Titan

Mar 17, 2026
pulisher
Mar 17, 2026

Gossamer Bio: Q4 Earnings Snapshot - marketscreener.com

Mar 17, 2026
pulisher
Mar 17, 2026

Gossamer Bio 2025 10-K: Revenue $48.5M, Net loss $170.4M - TradingView

Mar 17, 2026
pulisher
Mar 17, 2026

Gossamer Bio (NASDAQ: GOSS) 2025 loss widens as seralutinib Phase 3 misses goal - Stock Titan

Mar 17, 2026
pulisher
Mar 17, 2026

[10-K] Gossamer Bio, Inc. Files Annual Report | GOSS SEC FilingForm 10-K - Stock Titan

Mar 17, 2026

Gossamer Bio Inc (GOSS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
大文字化:     |  ボリューム (24 時間):